BCIQ Profiles

Company Profile Report

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson

Read the full 349 word article

How to gain access

Continue reading with a
two-week free trial.